Metabolic Dysfunction-Associated Steatotic Liver Disease
Health care professionals ‘thrilled’ with approval of first treatment for MASH
An analysis of the global online conversations of more than 1,600 healthcare professionals has revealed celebration at news of the approval of the first treatment for adults with metabolic dysfunction-associated steatohepatitis.
Food insecurity boosts fibrosis odds in HIV with diabetes, lowers MASLD odds in HIV alone
Food insecurity was associated with lower odds of metabolic dysfunction-associated steatotic liver disease among patients with HIV, although the presence of diabetes increased the odds of fibrosis in this population, according to data.
Q&A: NASPGHAN joins challenge to end hunger, funds ‘bold’ innovations for health equity
The White House has accepted a $25,000 commitment from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, which will help advance the administration’s goal to end hunger and nutrition disparities by 2030.
Agile scores ‘may be suitable alternative’ to routine liver biopsy in MASLD patients
Vibration-controlled transient elastography-based Agile scores accurately predicted liver-related events in patients with metabolic dysfunction-associated steatotic liver disease and “may be suitable alternatives” to routine liver biopsy.
VIDEO: Childhood food insecurity may play role in ‘booming’ rise of MASLD
In this video, Sarah L. Maxwell, MD, and Janet M. Wojcicki, PhD, MPH, discuss a reported link between food insecurity at age 4 years and an increased risk for metabolic dysfunction-associated steatotic liver disease among Latino children.
Low-dose aspirin ‘significantly’ reduced hepatic fat in MASLD by more than 10% vs. placebo
Daily low-dose aspirin “significantly reduced” hepatic fat quantity at 6 months compared with placebo among patients with metabolic dysfunction-associated steatotic liver disease, according to preliminary trial results published in JAMA.
Efruxifermin with GLP-1RA appears safe, reduces liver fat by 65% in MASH, diabetes
Efruxifermin with a glucagon-like peptide-1 receptor agonist was well-tolerated and reduced hepatic fat fraction and noninvasive markers of fibrosis among patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes.
SGLT2 inhibitors surpassed other antidiabetics as ‘viable option’ for MASLD in diabetes
Sodium-glucose cotransporter 2 inhibitors were associated with a higher likelihood of disease regression among patients with concomitant metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, data showed.
MAESTRO-NASH: Resmetirom 80 mg, 100 mg superior to placebo, ‘efficacious’ at 52 weeks
Resmetirom 80 mg and 100 mg outperformed placebo in disease resolution and improvement in liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis, according to 52-week results from the MAESTRO-NASH trial.
Threefold higher rate of cirrhosis, HCC linked to alcohol overconsumption in MASLD
Around 17% of patients with metabolic dysfunction-associated steatotic liver disease have or will be diagnosed with alcohol-related disease, which research shows is associated with a threefold higher rate of developing cirrhosis or cancer.